

Special Issue

Lipid Metabolism in Obesity and Diabetes, 2nd Edition

Message from the Guest Editors

This Special Issue is a continuation of our previous Special Issue, “Lipid Metabolism in Obesity and Diabetes 2023”. Obesity leads to a plethora of medical complications including coronary artery disease, hypertension, type 2 diabetes mellitus, insulin resistance and dyslipidemia. Furthermore, atherogenesis is associated with the above-mentioned diseases and cause early cardiovascular complications and increased mortality. Previously, both harmful and beneficial effects of organokines, such as adipokines, hepatokines and gut hormones, have been observed for obesity and diabetes, especially in the regulation of glucose and lipid metabolism, insulin sensitivity, inflammation, vascular senescence and endogenous oxidative stress. We welcome up-to-date reviews as well as clinical and original research articles studying lipid metabolism and/or organokine disturbances in the field of obesity; moreover, we welcome papers addressing related complications such as type 2 diabetes, dyslipidemias and atherosclerosis. The non-lipid effects of lipid-lowering and antidiabetic drugs in diabetes will also be covered.

Guest Editors

Dr. Hajnalka Lőrincz

Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary

Dr. Mariann Harangi

Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary

Deadline for manuscript submissions

closed (31 October 2024)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/198037

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).